Intravenous Oxycodone versus Intravenous Morphine in Cancer Pain: A Randomized, Open-Label, Parallel-Group, Active-Control Study

Table 2

Change in average, worst, and current NRS pain scores from baseline (Day 0).

Change in NRS from Day 0 (full analysis set)	Oxycodone (N = 33)		Morphine (N = 32)		value
	n	Mean ± SD	n	Mean ± SD
Change in average pain score from Day 0
On Day 1	33	−2.1 ± 2.5	32	−1.9 ± 1.7	>0.999^†
On Day 2	33	−3.0 ± 2.4	32	−1.9 ± 2.0	0.065^†
On Day 3	33	−3.3 ± 2.3	32	−2.6 ± 2.1	0.212^†
On Day 4	33	−3.3 ± 2.2	32	−2.9 ± 2.0	0.612^†
On Day 5	33	−3.5 ± 2.2	32	−3.1 ± 1.8	0.562^†
Percentage change
On Day 5, %	33	−56.7 ± 27.3	32	−51.9 ± 25.2	0.553^†
Change in worst pain score from Day 0
On Day 1	26	−1.8 ± 2.6	25	−1.8 ± 2.7	0.723^†
On Day 2	26	−2.9 ± 2.7	25	−1.7 ± 2.2	0.045^†
On Day 3	26	−3.2 ± 2.6	25	−2.8 ± 2.2	0.703^†
On Day 4	26	−3.2 ± 2.7	25	−2.7 ± 2.4	0.633^†
On Day 5	26	−3.5 ± 2.5	25	−2.5 ± 2.3	0.152^§
Change in current pain score from Day 0
On Day 1	26	−2.0 ± 3.0	25	−1.2 ± 1.8	0.541^†
On Day 2	26	−2.7 ± 2.7	25	−1.2 ± 2.0	0.035^†
On Day 3	26	−2.9 ± 2.7	25	−1.5 ± 2.1	0.072^†
On Day 4	26	−2.8 ± 2.6	25	−1.8 ± 1.8	0.293^†
On Day 5	26	−3.4 ± 2.6	25	−1.9 ± 1.6	0.020^§

NRS (LOCF): 0–10, 0—least pain, 10—most pain; ^†Wilcoxon rank sum test; ^§2-sample t-test; LOCF = last observed carried forward, NRS = Numerical Rating Score.